Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycine + n-acetylcysteine
- Development stage
- Phase 4
- Lead developer
- Baylor College of Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GlyNAC is a nutritional supplement combining glycine and N-acetylcysteine (NAC) that serves as precursors for glutathione synthesis in the body. This combination has been shown to improve glutathione deficiency, reduce oxidative stress, enhance mitochondrial function, decrease inflammation, improve insulin sensitivity, and support endothelial function. It has demonstrated potential benefits for age-related decline, metabolic health, and conditions characterized by high oxidative stress.
- Brand names
- GlyNAC
- Other names
- N-acetylcysteine plus glycineNAC + glycine
02
Targets
GSH (Glutathione synthesis / redox)
Beyond the preview
Go deeper on glycine + n-acetylcysteine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycine + n-acetylcysteine.